Histopathology Kidney Biopsy Panel 2 in UAE | 550 AED | DHA Licensed Laboratory

Executive Summary & Core Metrics

99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing

Advanced Light Microscopy, Immunohistochemistry (IHC), and Digital Photography for precise renal tissue evaluation. Hospital extraction only – sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety.

✓ Turnaround Time: Results delivered within 5 working days from specimen receipt.
✓ Clinical Guidance: Telephonic post-test consultation for result interpretation.
✓ Insurance Direct Billing Verification via WhatsApp +971 54 548 8731

Test Overview & Methodology

The Histopathology Kidney Biopsy Panel 2 is a comprehensive diagnostic assessment combining light microscopy, immunohistochemistry, and digital photography to identify and classify glomerular, tubulointerstitial, and vascular renal diseases. With an ISO-accredited laboratory, results are delivered within 5 working days, enabling timely clinical decisions for native and transplant kidney evaluations.

Feature	Our Panel (Histopathology Kidney Biopsy Panel 2)	Standard Histopathology Biopsy
Diagnostic Precision	IHC-based subtyping with digital image analysis; 99.9% reported sensitivity	Light microscopy only; may miss immune-mediated deposits
Methodology	Light Microscopy + IHC + Digital Photography (ISO compliant)	Light Microscopy alone
Turnaround Time	5 Working Days	7–10 working days typical
Collection Protocol	Hospital extraction only – accredited facility required	Hospital-based, not guaranteed standardized

Physician Insight & Safety Protocols

“Histopathological evaluation of renal tissue remains the cornerstone for diagnosing glomerulopathies and tubulointerstitial diseases. This panel integrates light microscopy with targeted immunohistochemistry to detect immune complex deposition and complement activation that standard stains may overlook. Correlation with clinical presentation, serologic markers, and imaging is essential for accurate staging and therapeutic planning. Any unexpected finding or discordance between the pathology report and the patient‘s clinical trajectory should prompt a multidisciplinary review.”

— Mr. Prabhakar Reddy Kalathoor, Specialist Diagnostic Radiology, DHA Registration ID: 61713011

Medication Advisory

Patients under immunosuppressive therapy, anticoagulants, or antihypertensive agents must continue their prescribed regimen unless explicitly instructed otherwise by their nephrologist. Biopsy interpretation may be influenced by concurrent pharmacotherapy; therefore, a complete medication history should accompany the tissue sample.

Exclusion Criteria & Safety Red Flags

Exclusion Criteria: Uncorrectable bleeding diathesis (INR >1.5, platelets <50,000/µL), active urinary tract infection, severe uncontrolled hypertension (>180/110 mmHg), or solitary kidney without urological clearance.
Emergency Red Flags (post-biopsy): Sudden severe flank pain, macroscopic hematuria with clots, syncope, fever >38°C, or significant drop in urine output (<500 mL/24h). Immediate ER evaluation is required.
Pediatric Note: Minors require explicit parental consent as per Federal Decree-Law No. 4 of 2016 on Medical Liability; all data handled under UAE PDPL.

Patient FAQ & Clinical Guidance

1. What specific renal conditions does this panel identify that a standard biopsy may miss?

This panel detects glomerular, tubular, and interstitial kidney diseases with 99.9% diagnostic sensitivity using advanced immunohistochemistry (IHC) and digital imaging analysis. It identifies immune complexes, complement deposits, and subtle podocyte changes often invisible on routine microscopy alone, providing precise classification for conditions such as membranous nephropathy, IgA nephropathy, and crescentic glomerulonephritis.

2. What is the turnaround time and how is the biopsy specimen collected and transported?

Results are delivered within 5 working days after specimen receipt. The kidney biopsy must be performed in an accredited hospital setting by a qualified interventional radiologist or nephrologist. The extracted tissue is immediately fixed in formalin and transported via secure medical courier in temperature-controlled packaging to our ISO-accredited laboratory.

3. Is this panel validated for transplant kidney biopsies and what safety measures are in place?

Yes, the panel is validated for both native and transplant kidney biopsies using dedicated requisition protocols. Safety is ensured through strict exclusion criteria, real-time post-procedure monitoring, and compliance with Federal Decree-Law No. 4 of 2016 on Medical Liability for clinical follow-up and patient consent.

UAE Regulatory & Data Privacy Adherence

Your Health Data. Your Rights. Our Commitment.

DNA Labs UAE operates in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All patient data generated from the Histopathology Kidney Biopsy Panel 2 — including clinical history, imaging records, and pathology results — is encrypted, access-controlled, and processed exclusively within secure UAE-based infrastructure. No data is shared with third parties without explicit patient consent. Our DHA-licensed facility (License No. 1143) adheres to ISO 9001:2015 quality management standards and undergoes regular audits to ensure full regulatory alignment.

Clinical & Logistical Metadata

Test Name	Histopathology Kidney Biopsy Panel 2
Price (AED)	550
Turnaround Time	5 Working Days
Sample Type / Matrix	Kidney Tissue (Biopsy Specimen)
Methodology Used	Light Microscopy + Immunohistochemistry (IHC) + Digital Photography
ICD-10-CM Code	N05.9
LOINC Code	34574-6
DHA Facility License & Address	License No. 1143 \| Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE